← Leaderboards
Rosemary J Akhurst
University Of California San Francisco
$18,718,924
Attributed
$19,394,337
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,394,337 · 14
By mechanism
R01$14,461,651 · 7
P30$2,991,637 · 2
S10$760,906 · 2
R56$511,463 · 1
R21$359,561 · 1
P01$309,119 · 1
Top collaborators
- Allan Balmain2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Douglas Hanahan$19,892,030
- Kevin M Shannon$44,683,939
- Frank Patrick McCormick$56,513,144
- Allan Balmain$39,243,725
- Michael D Prados$7,364,703
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMolecularResponseGeneticIn VivoMouse ModelCellsPharmaceutical PreparationsPathway InteractionsGenesInvestigationAffectSignal PathwayDrug DevelopmentAngiogenesisCharacteristicsMutationPre-ClinicalIn VitroCancer ModelTransforming Growth FactorsBiological MarkersSignal TransductionTumor
Grant awards (55)
Protein tyrosine phosphatase non-receptor 14 in vascular stability and remodeling$714,066
R01 · FY2025 · HL · contact PI
A network approach to interrogate cellular plasticity and drug resistance in cancer$679,232
R01 · FY2025 · CA · contact PI
Protein tyrosine phosphatase non-receptor 14 in vascular stability and remodeling$699,671
R01 · FY2024 · HL · contact PI
A network approach to interrogate cellular plasticity and drug resistance in cancer$671,594
R01 · FY2024 · CA · contact PI
Protein tyrosine phosphatase non-receptor 14 in vascular stability and remodeling$727,866
R01 · FY2023 · HL · contact PI
Preclinical Therapeutics Shared Resource$443,109
P30 · FY2022 · CA · contact PI
Preclinical Therapeutics Shared Resource$421,573
P30 · FY2021 · CA · contact PI
Advancing the translatability of mouse models for cancer immunotherapy$80,750
R01 · FY2021 · CA · contact PI
Advancing the translatability of mouse models for cancer immunotherapy$720,801
R01 · FY2020 · CA · contact PI
Preclinical Therapeutics Shared Resource$435,239
P30 · FY2020 · CA · contact PI
Advancing the translatability of mouse models for cancer immunotherapy$576,547
R01 · FY2019 · CA · contact PI
Preclinical Therapeutics Shared Resource$440,251
P30 · FY2019 · CA · contact PI
PerkinElmer Quantum GX CT-imager$342,962
S10 · FY2019 · OD · contact PI
Advancing the translatability of mouse models for cancer immunotherapy$67,968
R01 · FY2019 · CA · contact PI
Advancing the translatability of mouse models for cancer immunotherapy$587,737
R01 · FY2018 · CA · contact PI
Circulating cells as tools to study vascular pathobiology of HHT$443,398
R01 · FY2018 · HL · contact PI
Preclinical Therapeutics Shared Resource$438,994
P30 · FY2018 · CA · contact PI
Preclinical Therapeutics Shared Resource$10,744
P30 · FY2018 · CA · contact PI
Preclinical Therapeutics Shared Resource$8,604
P30 · FY2018 · CA · contact PI
Preclinical Therapeutics Shared Resource$3,500
P30 · FY2018 · CA · contact PI
Circulating cells as tools to study vascular pathobiology of HHT$516,647
R01 · FY2017 · HL · contact PI
Circulating cells as tools to study vascular pathobiology of HHT$518,186
R01 · FY2016 · HL · contact PI
Circulating cells as tools to study vascular pathobiology of HHT$550,711
R01 · FY2015 · HL · contact PI
Circulating cells as tools to study vascular pathobiology of HHT$511,463
R56 · FY2014 · HL · contact PI
Acquired Resistance to TGFBR1 inhibitors and cancer stem cell outgrowth$157,938
R21 · FY2013 · CA · contact PI
TGFBM2 in Development and Disease$357,388
R01 · FY2012 · GM · contact PI
Acquired Resistance to TGFBR1 inhibitors and cancer stem cell outgrowth$201,623
R21 · FY2012 · CA · contact PI
IVIS Spectrum Imaging System$417,944
S10 · FY2011 · RR · contact PI
TGFBM2 in Development and Disease$350,499
R01 · FY2011 · GM · contact PI
PRECLINICAL THERAPEUTICS$165,143
P30 · FY2011 · CA · contact PI
TGFBM2 in Development and Disease$66,253
R01 · FY2011 · GM · contact PI
Functional analysis of Tgfbm3 locus in vascular development and disease$567,457
R01 · FY2010 · HL · contact PI
TGFBM2 in Development and Disease$354,015
R01 · FY2010 · GM · contact PI
"Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"$292,084
R01 · FY2010 · CA · contact PI
PRECLINICAL THERAPEUTICS$162,838
P30 · FY2010 · CA · contact PI
Functional analysis of Tgfbm3 locus in vascular development and disease$569,473
R01 · FY2009 · HL · contact PI
TGFBM2 in Development and Disease$347,625
R01 · FY2009 · GM · contact PI
"Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"$295,736
R01 · FY2009 · CA · contact PI
PRECLINICAL THERAPEUTICS$161,222
P30 · FY2009 · CA · contact PI
Functional analysis of Tgfbm3 locus in vascular development and disease$547,678
R01 · FY2008 · HL · contact PI
"Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"$296,906
R01 · FY2008 · CA · contact PI
PRECLINICAL THERAPEUTICS$162,636
P30 · FY2008 · CA · contact PI
Functional analysis of Tgfbm3 locus in vascular development and disease$546,471
R01 · FY2007 · HL · contact PI
TGF Signaling in Anti-Rejection Drug-Induced NMSC$309,119
P01 · FY2007 · AR · contact PI
"Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"$295,961
R01 · FY2007 · CA · contact PI
PRECLINICAL THERAPEUTICS$137,784
P30 · FY2007 · CA · contact PI
Functional analysis of Tgfbm3 locus in vascular development and disease$550,818
R01 · FY2006 · HL · contact PI
GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO$306,063
R01 · FY2004 · GM
GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO$79,538
R01 · FY2004 · GM
GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO$53,064
R01 · FY2004 · GM
GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO$306,063
R01 · FY2003 · GM
GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO$113,625
R01 · FY2003 · GM
TGF-Beta signaling in anti-rejection drug induced NMSC$0
P01 · FY2003 · AR
GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO$306,063
R01 · FY2002 · GM
GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO$303,697
R01 · FY2001 · GM